XNASOBIO
Market cap207mUSD
Jan 10, Last price
5.47USD
1D
1.86%
1Q
7.68%
IPO
-52.43%
Name
Health Sciences Acquisitions Corp 2
Chart & Performance
P/E
—
P/S
75.34
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
3m
-21.88%
Net income
-49m
L+46.16%
CFO
-46m
L+57.49%
Profile
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | 2,760 -21.88% | 3,533 -551.79% | ||
Cost of revenue | 34,008 | 22,267 | ||
Unusual Expense (Income) | ||||
NOPBT | (31,248) | (18,734) | ||
NOPBT Margin | ||||
Operating Taxes | (222) | |||
Tax Rate | ||||
NOPAT | (31,248) | (18,512) | ||
Net income | (49,120) 46.16% | (33,608) 46.03% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 254 | (92,401) | ||
BB yield | -0.08% | |||
| Debt | ||||
Debt current | 1,298 | 697 | ||
Long-term debt | 2,725 | 11,173 | ||
Deferred revenue | 14,923 | 13,103 | ||
Other long-term liabilities | 196 | |||
Net debt | (86,067) | (74,410) | ||
| Cash flow | ||||
Cash from operating activities | (46,127) | (29,289) | ||
CAPEX | (78) | (591) | ||
Cash from investing activities | 10,687 | (64,122) | ||
Cash from financing activities | 46,215 | 103,257 | ||
FCF | (30,406) | (21,068) | ||
| Balance | ||||
Cash | 87,595 | 83,785 | ||
Long term investments | 2,495 | 2,495 | ||
Excess cash | 89,952 | 86,103 | ||
Stockholders' equity | (248,860) | (148,288) | ||
Invested Capital | 334,162 | 224,308 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 33,225 | 14,989 | ||
Price | 9.13 | |||
Market cap | 303,346 | |||
EV | 217,279 | |||
EBITDA | (30,961) | (18,512) | ||
EV/EBITDA | ||||
Interest | ||||
Interest/NOPBT | ||||